HFNC & NIV
immediate assessment
before choosing a device, check these first
- consciousness and airway protection, hemodynamics, active vomiting or high aspiration risk, ability to fit a mask
- if any of these fail → HFNC/NIV is not the answer, prepare for intubation instead, see contraindications below
- assumes acute respiratory failure has already been recognized and classified, see acute respiratory failure
- get a baseline gas (ABG preferred, VBG if arterial access will take time), SpO₂, RR and vitals before starting either device
- explain the mask or cannula to the patient before starting, early tolerance predicts overall tolerance
define & classify
| device | what it delivers | best fit |
|---|---|---|
| HFNC | humidified oxygen at up to 60 L/min, FiO₂ up to 100%, a small unmeasured CPAP-like effect (roughly 5 cmH₂O) | hypoxemic failure, well tolerated, allows talking/eating/drinking |
| CPAP | a single continuous pressure (EPAP) throughout the cycle | cardiogenic pulmonary edema, hypoxemia with preserved ventilation |
| BiPAP | two pressures, inspiratory (IPAP) and expiratory (EPAP); the IPAP–EPAP gap drives alveolar ventilation | hypercapnic failure, needs ventilatory support not just oxygenation |
HFNC delivers heated, humidified, high-flow oxygen by nasal cannula; NIV (CPAP/BiPAP) delivers positive pressure by mask or helmet in a spontaneously breathing patient, not invasive ventilation.
initial management
choose HFNC when
- hypoxemic failure: HFNC over conventional oxygen and HFNC over NIV as first-line support are both conditional recommendations (1)
- immunocompromised: HFNC alone is a reasonable first line; alternating with NIV adds no mortality or intubation benefit and is less tolerated (2); NIV only for a separate indication (e.g. cardiogenic edema, COPD), not immunosuppression alone
- the patient needs planned breaks from NIV
- post-extubation at low/moderate risk of failure, or post-operatively at low risk of respiratory complications
start → flow 30–40 L/min, FiO₂ 40–50%; titrate flow up to 60 L/min and FiO₂ to target SpO₂ 94–98% (88–92% if at risk of hypercapnic failure)
choose NIV (CPAP/BiPAP) when
- acidotic COPD exacerbation: BiPAP; RR usually > 20–24, pH ≤ 7.35, PaCO₂ > 45 mmHg despite optimal bronchodilator / steroid therapy (strong recommendation (3)); NIV before HFNC in this group (1)
- cardiogenic pulmonary edema without shock: CPAP or BiPAP
- post-operative high risk of respiratory complications, and prevention of post-extubation failure in high-risk patients (age > 65 with cardiac or respiratory disease): probably beneficial, weaker evidence
- a do-not-intubate patient as a ceiling of care: BiPAP can be the only ventilatory support offered when invasive ventilation is not appropriate
- palliative dyspnea from terminal malignancy where the patient wants symptomatic relief
start → CPAP 5 cmH₂O, or BiPAP EPAP 4–5 cmH₂O / IPAP 10–12 cmH₂O (IPAP at least 4–5 cmH₂O above EPAP)
contraindications to NIV / HFNC
- reduced consciousness or inability to protect the airway (relative in a controlled, monitored COPD trial, but reassess constantly)
- respiratory or cardiac arrest
- hemodynamic instability, uncontrolled arrhythmia
- facial trauma, burns, or surgery preventing a seal; fixed upper airway obstruction
- active vomiting or high aspiration risk
- inability to clear secretions
reassess
- NIV → repeat ABG; reassess RR, work of breathing and mental state within 1–2 h of starting or any pressure change; better pH or RR (ideally both) in this window predicts success
ROX index
ROX index = (SpO₂/FiO₂) ÷ respiratory rate, calculated for a patient on HFNC only.
calculator ROX index · MDCalc ↗︎
check at 2 h, 6 h and 12 h after starting HFNC (4)
| ≥ 4.88reassuring | lower risk of needing intubation; continue and reassess at the next checkpoint |
| 3.85–4.87indeterminate | reassess sooner than the next scheduled checkpoint; the trend matters more than one value |
| < 3.85high risk | predicts likely HFNC failure, escalate now rather than waiting for further decline |
derived and validated mainly in pneumonia-related hypoxemic failure; more reliable at 12 h than at 2 h; supports a decision, does not replace judgment.
either device → continuous SpO₂, regular vital signs, and direct reassessment of work of breathing, not just the numbers
advanced management
HFNC
- titrate flow before FiO₂ where comfort allows, higher flow improves CO₂ washout and comfort as well as oxygenation
- humidifier 37°C for full humidification; too hot or poorly tolerated → 31–34°C improves comfort without meaningful loss of effect, especially at higher FiO₂ (5)
- humidification must be running before use, dry gas at high flow thickens secretions and irritates the nasal mucosa
NIV
- CPAP → titrate in 2.5–5 cmH₂O increments guided by comfort, work of breathing and SpO₂
- BiPAP → IPAP up in 2–5 cmH₂O steps roughly every 10–15 min by tidal volume, RR and pH, keeping IPAP at least 4–5 cmH₂O above EPAP; EPAP up in 2–3 cmH₂O steps for persistent hypoxemia
- reassess with serial gases, do not chase a pressure ceiling number without checking response
adjuncts
- awake prone positioning for a spontaneously breathing hypoxemic patient on HFNC not yet needing intubation; as many hours per day as tolerated
- agitation or claustrophobia limiting an appropriate NIV trial: cautious low-dose opioid (e.g. morphine 2.5 mg subcutaneous) can settle it without significant respiratory depression; involve a senior before sedating anyone on NIV
- intubation likely → preoxygenate with NIV, not a face mask, if significantly hypoxemic (6); next step: mechanical ventilation
troubleshooting
- mask leak or poor seal → re-size or re-fit the mask before increasing pressures
- patient fighting the mask, agitated → coach and reassure first; cautious low-dose opioid only if intolerance, not hypoxemia, is the limit
- gastric distension → insert a nasogastric tube, especially with impaired consciousness or reduced motility
- desaturating despite maximum flow/FiO₂ or pressures → stop; reassess for pneumothorax, mucus plugging, or a new process; do not escalate settings blindly
- thickened secretions, or patient too hot, on HFNC → check humidifier function; temperature down toward 31°C settles discomfort and dryness without stopping the trial
- no improvement in RR or pH within 1–2 h → this is failure, stop trialling and escalate
escalation / ICU
call ICU / anesthesia urgently for
- ROX index < 3.85 or a falling trend at any checkpoint
- no improvement in pH, RR or oxygenation within 1–2 h of starting NIV, or within a few hours on HFNC
- worsening consciousness or new inability to protect the airway
- hemodynamic instability
- inability to clear secretions, or an interface the patient cannot tolerate despite adjustment
- persistent or worsening acidosis on repeat gas
- respiratory arrest, or any new contraindication developing on treatment
failing HFNC or NIV = decision now, not a longer trial; delaying intubation past this point is associated with worse outcomes than intubating promptly.
pearls & pitfalls
- choosing the device is about the phenotype (hypoxemic vs hypercapnic, cause), not just how sick the patient looks
- NIV in de novo hypoxemic failure without hypercapnia or cardiogenic edema is debated; most current guidance and trials default to HFNC first-line for that group (7)
- a poorly tolerated tight mask fails whatever the pressures: fit and comfort are part of the treatment
- controlled oxygen targets (88–92%) on a device are not under-treatment in a hypercapnic patient, they are the correct target
sources
dosing above follows international guidance. Verify against the current Kuwait / MOH or hospital protocol where locally sensitive.
go deeper the full MOC+ Acute Medicine set covers the on-call essentials.
More clinical resources in the MOC+ Library →
Last updated · September 2026